First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

Sara Lonardi,Marta Schirripa,Federica Buggin,Lorenzo Antonuzzo,Barbara Merelli,Giorgia Boscolo,Saverio Cinieri,Samantha Di Donato,Riccardo Lobefaro,Roberto Moretto,Vincenzo Formica,Alessandro Passardi,Vincenzo Ricci,Nicoletta Pella,Mario Scartozzi,Fable Zustovich,Vittorina Zagonel,Matteo Fassan,Luca Boni,Fotios Loupakis

First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

2020

4002Background: Data on first-line treatment efficacy in elderly patients are limited. Many analyses adopt a questionable cut-off of 65 years and specific evidence with anti-EGFRs is low. FOLFOX-pa...

Keywords:

Colorectal cancer
Oncology
Internal medicine
FOLFOX
Pathology
first line
Medicine
Wild type
Panitumumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations